US PHARMACEUTICAL industry consultant company EvaluatePharma has published its predictions for 2018 top 10 drug sales in the country, with only minor changes in the rankings from 2017.
More than doubling the second placegetter, Abbvie's Humira (adalimumab) is estimated to take out the top spot at $20.2b (up from around $19b in 2017), followed by Celgene's Revlimid (lenalidomide) with $9.2b.
Fourth to 10th spots are anticipated to each bring in a little over $6b, starting with Regeneron/Bayer's Eylea, Roche's Avastin, Rituxin and Herceptin, followed by J&J's Remicade.
Merck & Co's Keytruda brings up ninth position and J&J/Bayer's Xarelto 10th - see more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Feb 18
